e-Ultimaster

Overview

  • 37,198 patients enrolled: The biggest real world BP-DES registry in the world.
  • Excellent performance with a TLF rate < 5% in all continents and stent thrombosis rate < 1%.

Study Design

clinical_evidence_e_ultimaster_study_design.png

Primary Endpoint

Target lesion failure at 1 year

・Cardiac death, target vessel MI or clinically driven target lesion revascularization

Secondary Endpoint

Safety

・Cardiac death/myocardial infarction
・Stent thrombosis (according to ARC definitions; acute, subacute, and late)
・Major vascular and bleeding complications
 

Efficacy and patient-oriented endpoints

・Target lesion revascularization (TLR)
・Target vessel failure (TVF)  
   - Cardiac death, target vessel MI or clinically driven target vessel revascularization
・Patient-oriented composite endopoint (POCE)  
   - All-cause death, any MI or any coronary revascularization

Patient and lesion characteristics 

Image

clinical_evidence_e_ultimaster_patient_and_leasion_characteristics
 

Patient background

Male 76%
Diabetes 28%
Smoking 24%
Hypertension 68%
Hypercholesterolemia 60%
BMI≧30 25%
Age 64 years
CCS 45%
NSTE-ACS 36%
STEMI 20%
Radial access    
  CCS 80%
  NSTE-ACS 84%
  STEMI 83%
DAPT at 1 year    
  All patients 67%
  CCS 65%
  NSTE-ACS 68%
  STEMI 69%

Result

5-year clinical outcomes

clinical_evidence_e_ultimaster_clinical_outcomes

 

Reference